Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | CPT2 | P23786 | 2/20 | 0.43 |
| ▸ | CPT1A | P50416 | 2/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25384043 | 0.89 | ABHD6 (0.50) | ABHD6MEN1KMT2AS1PR5HRH3 | |
| SCHEMBL30678858 | 0.86 | ABHD6 (0.48) | ABHD6MEN1KMT2AS1PR5HRH3 | |
| SCHEMBL22366352 | 0.83 | S1PR5 (0.46) | ABHD6S1PR5HRH3CPT2CPT1A | |
| SCHEMBL22319878 | 0.81 | ABHD6 (0.54) | ABHD6MEN1KMT2AS1PR5HRH3 | |
| SCHEMBL22319858 | 0.79 | ABHD6 (0.55) | ABHD6S1PR5HRH3CPT2CPT1A | |
| SCHEMBL8188555 | 0.79 | HRH3 (0.47) | ABHD6MEN1KMT2AS1PR5HRH3 | |
| SCHEMBL22319845 | 0.78 | ABHD6 (0.54) | ABHD6S1PR5HRH3CPT2CPT1A | |
| SCHEMBL20983789 | 0.78 | ABHD6 (0.69) | ABHD6S1PR5HRH3CPT2CPT1A | |
| SCHEMBL9512181 | 0.75 | KDM4C (0.44) | MEN1KMT2AS1PR5HRH3HTR7 | |
| SCHEMBL28864977 | 0.74 | ABHD6 (0.49) | ABHD6MEN1KMT2ACPT2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2023-12-05 | — | — | US | disclosed |
| EP-3700911-B1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2023-09-06 | — | — | EP | disclosed |
| EP-3700911-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier SAS (FR) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | C1R, F12, RDX | ABHD6 2427/4885MEN1 592/4885KMT2A 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.